Wolfe Research Turns Bullish on Celldex, Upgrading to Outperform and Citing Stronger 2026 Catalysts

Wolfe Research upgrades Celldex Therapeutics to Outperform from Peer Perform, citing stronger 2026 catalysts and depressed valuation for rebound potential.